Five Years, Zero Exacerbations: Does Sustained Control Ever Earn Its Way to Stopping
A patient who meets essentially every published criterion for stopping a biologic, in a field that openly admits no standardized remission definition actually exists.
Ines M. retired from the county library system two years ago and has spent most of that time cataloging her own garden the way she used to catalog the periodicals room — a running spreadsheet of bloom dates, more thorough than strictly necessary. She started mepolizumab five years ago after a stretch of severe, non-allergic eosinophilic asthma that had put her in the hospital twice and kept her on maintenance prednisone for the better part of three years before that. She has not had an exacerbation, an oral steroid course, or an unscheduled visit in the three years since. What brought her back to this particular conversation, in her own words: “I have had roughly sixty of these injections. At some point I would like to know if I still need them.”
By any of the criteria that have actually been published for this question, she is close to an ideal candidate. Her lung function is normal, her exacerbation and symptom history clears three straight years of what researchers describe as clinical remission, she takes no oral corticosteroids, and her inflammatory markers have stayed suppressed throughout. The discontinuation literature’s frequently cited five-year minimum before attempting withdrawal is a number Ines is on the edge of clearing, not comfortably past — and the one randomized trial to actually test stopping is less reassuring than her chart looks. COMET randomized patients who had taken mepolizumab continuously for at least three years, all of them doing well enough on it to be randomized at all, to stop or to continue; those who stopped reached their first clinically significant exacerbation sooner, at a hazard ratio of 1.61, with blood eosinophils rebounding roughly sixfold by week 52. Ines is not outside that population. She is well inside it, which means COMET is describing her rather than someone with a thinner treatment history behind them. And GINA's own 2025 framework draws a real distinction her chart does not yet resolve: what she has documented is clinical remission, the absence of symptoms and exacerbations. Complete, or pathophysiological, remission is a higher bar — normal lung function plus the absence of bronchial hyperresponsiveness and airway inflammation on more objective testing — and nobody has actually checked whether she clears that second, stricter definition.
Five years in, asking whether the needle is still earning its place
Read against the actual published criteria for this decision, she is close to the textbook candidate: three straight years of clinical remission, zero oral steroid courses, normal lung function throughout, biomarkers suppressed, and treatment duration right at the five-year threshold the literature most commonly cites for reducing early relapse risk. I would support a structured discontinuation trial now rather than asking her to accumulate more years on a drug she may no longer need.
I would slow down on reading “sustained control on treatment” as the same claim as “sustained control off treatment.” The discontinuation literature itself is explicit that no standardized remission criteria exist yet, and COMET is the concrete version of my worry: every patient in it had at least three continuous years on mepolizumab and was doing well enough to be randomized, and stopping still shortened time to first exacerbation at a hazard ratio of 1.61, with eosinophils back up roughly sixfold at a year. A long, successful run on the drug did not protect that cohort. Five years on the drug tells us the drug worked. It does not, on its own, tell us what happens when it stops.
I am not arguing she should stay on mepolizumab indefinitely — I am arguing her chart answers “has she done well on treatment,” not the actual question in front of us, which is what happens when we take it away.
There is a real distinction in GINA’s own 2025 framework that neither of you has fully engaged yet: clinical remission, which is what her chart genuinely documents, versus complete or pathophysiological remission, which additionally requires confirming the absence of bronchial hyperresponsiveness and airway inflammation on more objective testing. Nobody has run that testing. Before we frame this as a binary between stopping now and staying on indefinitely, I would want that specific gap closed — not because it will necessarily change the answer, but because it is a real, checkable question this conversation has been having without it.
Agreed: continue mepolizumab unchanged for now, and complete formal methacholine challenge and FeNO testing before revisiting discontinuation — framed to Ines not as a delay but as answering a real, specific question her chart has not yet answered.
Not agreed: whether, if she clears the stricter complete-remission testing, discontinuation should happen abruptly or via a gradual dose-interval extension. The pulmonologist favors a defined stop date; the allergist favors extending her dosing interval first as an intermediate step. Left for the visit after her testing results return.